We want to see if recession concerns hit operating profit of pharmaceutical companies in Q1 FY19, says Anmol Ganjoo, pharmaceutical analyst of JM Financial Institutional Securities.
Speaking on pricing erosion, Ganjoo said generic players like Mylan and Tevas was complaining on the current pricing scenario and that was further validated by Indian companies like Sun Pharmaceutical Industries and Lupin.
However, in terms of evidence, we haven’t seen that pricing has hit any kind of bottom yet, Ganjoo said.
In terms of the regulatory compliance, "We got some positive news on the two facilities being cleared. So, now the onus is on the companies to reflect that confidence and we will watch them fairly closely going forward," Ganjoo said to CNBC-TV18.